Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity
Avtorji:Vlačić, Gregor (Avtor)
Hoda, Mir Alireza (Avtor)
Klikovits, Thomas (Avtor)
Sinn, Katharina (Avtor)
Gschwandtner, Elisabeth (Avtor)
Mohorčič, Katja (Avtor)
Schelch, Karin (Avtor)
Pirker, Christine (Avtor)
Peter-Vörösmarty, Barbara (Avtor)
Brankovic, Jelena (Avtor)
Čufer, Tanja (Avtor)
Rozman, Aleš (Avtor)
Kern, Izidor (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute to MPM aggressiveness and it was suggested that subgroups of MPM patients could benefit from FGFR-targeted inhibitors. In the current investigation, we determined the expression of all four FGFRs (FGFR1-FGFR4) by immunohistochemistry in tissue samples from 94 MPM patients. From 13 of these patients, we were able to establish stable cell lines, which were subjected to FGFR1-4 staining, transcript analysis by quantitative RT-PCR, and treatment with the FGFR inhibitor infigratinib. While FGFR1 and FGFR2 were widely expressed in MPM tissue and cell lines, FGFR3 and FGFR4 showed more restricted expression. FGFR1 and FGFR2 showed no correlation with clinicopathologic data or patient survival, but presence of FGFR3 in 42% and of FGFR4 in 7% of patients correlated with shorter overall survival. Immunostaining in cell lines was more homogenous than in the corresponding tissue samples. Neither transcript nor protein expression of FGFR1-4 correlated with response to infigratinib treatment in MPM cell lines. We conclude that FGFR3 and FGFR4, but not FGFR1 or FGFR2, have prognostic significance in MPM and that FGFR expression is not suffcient to predict FGFR inhibitor response in MPM cell lines.
Ključne besede:malignant pleural mesothelioma, fibroblast growth factor receptors, azbestos, immunotherapy, chemotherapy, genomic analysis, infigratinib
Leto izida:2019
Založnik:MDPI
Izvor:Švica
UDK:616-006
ISSN pri članku:2073-4409
OceCobissID:519958809 Povezava se odpre v novem oknu
COBISS_ID:2048535409 Povezava se odpre v novem oknu
DOI:10.3390/cells8091091 Povezava se odpre v novem oknu
Opombe:Soavtorji iz Slovenije: Katja Mohorcic, Tanja Cufer, Ales Rozman, Izidor Kern; Nasl. z nasl. zaslona; Opis vira z dne 17. 9. 2019; Št. prispevka: 1091;
Število ogledov:326
Število prenosov:149
Datoteke:URL URL - Predstavitvena datoteka, za dostop obiščite https://www.mdpi.com/2073-4409/8/9/1091/pdf
 
Nadgradivo:Cells
MDPI
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© 2019 by the authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:16.09.2019

Nazaj